Cognition Ptb Ratio from 2010 to 2024

CGTX Stock  USD 0.40  0.01  2.44%   
Cognition Therapeutics PTB Ratio yearly trend continues to be fairly stable with very little volatility. PTB Ratio is likely to outpace its year average in 2024. PTB Ratio is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on Cognition Therapeutics' equity relative to its net asset value. View All Fundamentals
 
PTB Ratio  
First Reported
2010-12-31
Previous Quarter
2.26665441
Current Value
2.38
Quarterly Volatility
3.19839294
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 239.4 K, Interest Expense of 25.6 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Latest Cognition Therapeutics' Ptb Ratio Growth Pattern

Below is the plot of the Ptb Ratio of Cognition Therapeutics over the last few years. It is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value. Cognition Therapeutics' PTB Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ptb Ratio10 Years Trend
Slightly volatile
   Ptb Ratio   
       Timeline  

Cognition Ptb Ratio Regression Statistics

Arithmetic Mean(2.88)
Coefficient Of Variation(111.16)
Mean Deviation2.72
Median(4.79)
Standard Deviation3.20
Sample Variance10.23
Range7.5351
R-Value0.78
Mean Square Error4.30
R-Squared0.61
Significance0.0006
Slope0.56
Total Sum of Squares143.22

Cognition Ptb Ratio History

2024 2.38
2023 2.27
2022 1.51
2021 2.74
2020 -4.11

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Ptb Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
PTB Ratio 2.27  2.38 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.